FENC
Fennec Pharmaceuticals Inc.
$6.70
-$0.15(-2.19%)
35
Overall
40
Value
27
Tech
39
Quality
Market Cap
$236.01M
Volume
54.07K
52W Range
$5.02 - $9.92
Target Price
$15.14
Company Overview
| Mkt Cap | $236.01M | Price | $6.70 |
| Volume | 54.07K | Change | -2.19% |
| P/E Ratio | -867.7 | Open | $6.85 |
| Revenue | $29.6M | Prev Close | $6.85 |
| Net Income | $-272.0K | 52W Range | $5.02 - $9.92 |
| Div Yield | N/A | Target | $15.14 |
| Overall | 35 | Value | 40 |
| Quality | 39 | Technical | 27 |
No chart data available
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Sector: Healthcare
Industry: Biotechnology
Latest News
Fennec Showcases New PEDMARK Data at 2026 ASCO
TipRanks Auto-Generated Newsdesk•6 days ago
Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (ABCL) and Fennec Pharmaceuticals (FENC)
Catie Powers•7 days ago
Fennec Pharmaceuticals (FENC) Receives a Buy from Wedbush
TipRanks Auto-Generated Intelligence Newsdesk•13 days ago
Fennec Backs New PEDMARK Study Expanding Cisplatin Ototoxicity Research to Adult Cancers
TipRanks Canadian Auto-Generated Newsdesk•22 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | FENC | $6.70 | -2.2% | 54.07K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Fennec Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW